Role of Cerebrospinal Fluid Biomarkers in Clinical Trials for Alzheimer's Disease Modifying Therapies

Until now, a disease-modifying therapy (DMT) that has an ability to slow or arrest Alzheimer's disease (AD) progression has not been developed, and all clinical trials involving AD patients enrolled by clinical assessment alone also have not been successful. Given the growing consensus that the...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Korean J Physiol Pharmacol
Asıl Yazarlar: Kang, Ju-Hee, Ryoo, Na-Young, Shin, Dong Wun, Trojanowski, John Q, Shaw, Leslie M.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: The Korean Physiological Society and The Korean Society of Pharmacology 2014
Konular:
Review Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4296032/
https://ncbi.nlm.nih.gov/pubmed/25598657
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4196/kjpp.2014.18.6.447
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller